Measuring heart muscle energy with a special scan in people with heart disease
Uses a special scan to measure heart muscle energy in people with heart disease.
Plain-language title generated from the registry record
Registry title: 31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT07912086
- Record updated
- 3 November 2026
- Original description
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS).Read full original descriptionShow less
Myocardial Energetic Phenotyping and Prognostic Value Across the Cardiac Disease Spectrum: A 31P Magnetic Resonance Spectroscopy Study
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS).
And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.
By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.
Inclusion: Age >= 18 years; Healthy volunteers, OR; Clinical diagnosis of cardiac disease, including non-ischemic cardiomyopathy (hypertrophic, amyloid, or inflammatory), ischemic cardiomyopathy, hypertensive heart disease, or valvular heart disease, OR; Inherited metabolic cardiomyopathies; Able to undergo CMR examination and provide written informed consent.
Exclusion: Any contraindication to CMR examination.